All > Tb

TB006 for Alzheimer's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Alzheimer's DiseaseTB006 - Drug
Eligibility
18 - 55
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the safety and effectiveness of a new Alzheimer's drug.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
vicagrel Capsules
1
MT1002 for Injection
1
Part A

Study Objectives

3 Primary · 10 Secondary · Reporting Duration: Day1-Day 75

Day1-Day 75
Number of subjects and rate of treatment-emergent adverse events, graded by CTCAE Version 5.0, by dose group and all active treatment vs. placebo
Through Day 75
Anti-TB006 antibodies
Pharmacokinetic (PK) profile/parameters: Area under the plasma concentration versus time curve (AUC)
Pharmacokinetic (PK) profile/parameters: Area under the plasma concentration versus time curve (AUC) through Day 29
Cerebrospinal Fluid
Pharmacokinetic (PK) profile/parameters: Maximum observed plasma concentration
Pharmacokinetic (PK) profile/parameters: Time at which maximum plasma concentration occurs
Pharmacokinetic (PK) profile/parameters: terminal elimination phase half life
Pharmacokinetic (PK) profile/parameters: total clearance
Pharmacokinetic (PK) profile/parameters: volume of distribution
Safety and tolerability
Through day 75
To determine the MTD of single doses of TB006 in healthy adult subjects
To determine the single-dose PK profile of TB006 in healthy adult subjects

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
vicagrel Capsules
1
MT1002 for Injection
1
Part A

Trial Design

2 Treatment Groups

TB006 70 mg - 5000 mg IV
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

48 Total Participants · 2 Treatment Groups

Primary Treatment: TB006 · Has Placebo Group · Phase 1

TB006 70 mg - 5000 mg IV
Drug
Experimental Group · 1 Intervention: TB006 · Intervention Types: Drug
Placebo
Other
PlaceboComparator Group · 1 Intervention: Sterile saline (Placebo) · Intervention Types: Other

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: day1-day 75

Who is running the clinical trial?

TrueBinding, Inc.Lead Sponsor
4 Previous Clinical Trials
440 Total Patients Enrolled
David Walling, MDPrincipal InvestigatorCollaborative Neuroscience Research
1 Previous Clinical Trials
65 Total Patients Enrolled
George Haig, PharmDStudy DirectorTrueBinding, Inc.
5 Previous Clinical Trials
1,278 Total Patients Enrolled

Eligibility Criteria

Age 18 - 55 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top